Abdulrahman Al-Mashdali: Targeted Therapies for CNS Involvement in CLL
Abdulrahman Al-Mashdali, Hematology Chief Fellow at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Therapeutic Advances in Hematology, adding:
”I’m pleased to share our newly published systematic review in Therapeutic Advances in Hematology:
‘Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review.’
CNS involvement in CLL/SLL is rare, diagnostically challenging, and historically associated with poor outcomes. In this systematic review, we analyzed 26 studies including 32 patients treated with novel targeted therapies.
Key findings:
- 94.1 percent overall response rate across 34 treatment regimens
- 55.9 percent complete responses and 38.2 percent partial responses
- Ibrutinib was the most frequently used targeted agent
- Venetoclax and ibrutinib–venetoclax combinations demonstrated encouraging activity
- Responses were observed even in patients with adverse biological features such as TP53 abnormalities, del(17p), and unmutated IGHV
While these findings are encouraging, the evidence remains largely based on case reports and small series. Prospective multicenter studies are needed to better define treatment sequencing, combination strategies, and the role of intrathecal therapy and radiotherapy.
I’m grateful to all my co-authors and colleagues who contributed to this work.”
Title: Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review
Authors: Abdulrahman F. Al-Mashdali, Mujahid O. Abdelraof, Raga M. Mukhtar, Shehab F. Mohamed,
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention